Program
fosnetupitant
Also written as “Fosnetupitant 235 mg solution” and “fosnetupitant/ palonosetron”.
Its studies are mostly in Vomiting, led by Helsinn Healthcare.
Furthest: phase 3, since Jan 4, 20182 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Helsinn Healthcare | 20 open or running | phase 3since Jan 4, 2018 | Jan 4, 2018 | none ahead |
Also a collaborator on its studies: george-clinical-pty-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2018First study: phase 3 study in VomitingFirst studyNCT03403712 · 404 enrolled · United States, Georgia
- Feb 11, 2025Phase 1 study in Healthy VolunteersNCT06840769 · 50 enrolled · Switzerland
TargetBeta
TACR1 →read by rule
“A prodrug of netupitant, a selective neurokinin 1 receptor (NK1R; TACR1) antagonist, ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aprepitantrule | Merck | phase 4 | 27 |
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06840769Healthy Volunteers · Switzerland | 1 | Terminated | Oct 18, 2023 | 50 |
| NCT03403712Vomiting · United States, Georgia | 3 | Completed | Sep 19, 2018 | 404 |
How it is read
Names in the registry
- “Fosnetupitant 235 mg solution”, 1 entry
- “fosnetupitant/ palonosetron”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.